AI-Powered app aims to transform colorectal cancer recovery monitoring

NCT ID NCT06685497

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests a digital platform that uses artificial intelligence to monitor colorectal cancer patients after surgery. Patients report symptoms through a mobile app, and the AI analyzes the data to flag issues with color-coded alerts. The goal is to see if this system boosts follow-up rates, patient satisfaction, and reduces unplanned hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a digital healthcare management platform with AI symptom monitoring and alerts
What this could lead to: If successful, this digital system could improve follow-up care for colorectal cancer patients, reducing unplanned hospital visits and enhancing quality of life.
What could go wrong: This is a single-center trial with 236 participants, so results may not apply broadly. The system relies on patient engagement with the app, which may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA

Contacts and locations

Locations

Shanghai Jiao Tong University School of Medicine, Renji Hospital
RECRUITING

Shanghai, 200135, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.